2024
Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform
Costello R, Waller K, Smith R, Mells G, Wong A, Schultze A, Mahalingasivam V, Herrett E, Zheng B, Lin L, MacKenna B, Mehrkar A, Bacon S, Goldacre B, Tomlinson L, Tazare J, Rentsch C. Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform. Communications Medicine 2024, 4: 238. PMID: 39562612, PMCID: PMC11576861, DOI: 10.1038/s43856-024-00664-y.Peer-Reviewed Original ResearchCOVID-19 hospitalisationSevere COVID-19 outcomesCOVID-19 related hospitalisationCOVID-19 outcomesCohort studyPopulation-based cohort studyHazard ratioPrimary care recordsDeath registration dataOpenSAFELY-TPP platformApproval of NHS EnglandConfidence intervalsEstimate hazard ratiosCox proportional hazards regressionProportional hazards regressionPre-specified confoundersAbsolute risk reductionOpenSAFELY platformCare recordsNHS EnglandConfounder adjustmentEligible individualsRegistration dataHazards regressionHospital recordsCare interruptions and mortality among adults in Europe and North America
Trickey A, Zhang L, Rentsch C, Pantazis N, Izquierdo R, Antinori A, Leierer G, Burkholder G, Cavassini M, Palacio-Vieira J, Gill M, Teira R, Stephan C, Obel N, Vehreschild J, Sterling T, Van Der Valk M, Bonnet F, Crane H, Silverberg M, Ingle S, Sterne J. Care interruptions and mortality among adults in Europe and North America. AIDS 2024, 38: 1533-1542. PMID: 38742863, PMCID: PMC11239093, DOI: 10.1097/qad.0000000000003924.Peer-Reviewed Original ResearchCare interruptionsMortality riskCohort studyHazard ratioAnalysis of cohort studiesAntiretroviral therapyCare of peopleRobust to sensitivity analysesMortality hazard ratioCrude mortality rateHazard of mortalityAntiretroviral therapy initiationObservational cohort studyAntiretroviral therapy startUninterrupted careFollow-up groupCareAssociated with adverse outcomesPWHCox regressionAdverse outcomesFollow-up timeMortality rateCompare hazardsComposite outcomePsychotropic prescribing after hospital discharge in survivors of critical illness, a retrospective cohort study (2012–2019)
Mansi E, Rentsch C, Bourne R, Guthrie B, Lone N. Psychotropic prescribing after hospital discharge in survivors of critical illness, a retrospective cohort study (2012–2019). Journal Of The Intensive Care Society 2024, 25: 171-180. PMID: 38737305, PMCID: PMC11081855, DOI: 10.1177/17511437231223470.Peer-Reviewed Original ResearchPsychotropic prescriptionsSurvivors of critical illnessCritical care survivorsPsychotropic prescribingCare groupHospital dischargeRetrospective cohort studyCritical careCritical illnessCohort studyHazard ratioMental health issuesCritical care groupHospitalised survivorsPsychotropic medicinesPotential confoundersSleep disturbanceHospitalised adultsHealth issuesHospitalised patientsIllnessSurvivorsPrescriptionClinical practiceCare
2023
Excess mortality in US Veterans during the COVID-19 pandemic: an individual-level cohort study
Weinberger D, Bhaskaran K, Korves C, Lucas B, Columbo J, Vashi A, Davies L, Justice A, Rentsch C. Excess mortality in US Veterans during the COVID-19 pandemic: an individual-level cohort study. International Journal Of Epidemiology 2023, 52: 1725-1734. PMID: 37802889, PMCID: PMC10749763, DOI: 10.1093/ije/dyad136.Peer-Reviewed Original ResearchConceptsExcess mortality ratesExcess mortalityComorbidity burdenHazard ratioCohort studyMortality rateVeterans Aging Cohort Study (VACS) IndexIndividual-level cohort studyVeterans AffairsCOVID-19 pandemicLarge integrated healthcare systemExcess mortality patternsHigher comorbidity burdenLower comorbidity burdenMost frail patientsCharlson Comorbidity IndexObservational cohort studyClinical risk groupsIntegrated healthcare systemLeast frailComorbidity indexFrail patientsPre-pandemic periodMedian ageUS veteransContribution of alcohol use in HIV/hepatitis C virus co‐infection to all‐cause and cause‐specific mortality: A collaboration of cohort studies
Trickey A, Ingle S, Boyd A, Gill M, Grabar S, Jarrin I, Obel N, Touloumi G, Zangerle R, Rauch A, Rentsch C, Satre D, Silverberg M, Bonnet F, Guest J, Burkholder G, Crane H, Teira R, Berenguer J, Wyen C, Abgrall S, Hessamfar M, Reiss P, Monforte A, McGinnis K, Sterne J, Wittkop L, Collaboration T. Contribution of alcohol use in HIV/hepatitis C virus co‐infection to all‐cause and cause‐specific mortality: A collaboration of cohort studies. Journal Of Viral Hepatitis 2023, 30: 775-786. PMID: 37338017, PMCID: PMC10526649, DOI: 10.1111/jvh.13863.Peer-Reviewed Original ResearchConceptsHepatitis C virusAntiretroviral therapyAlcohol useC virusHIV/hepatitis C virusHeavy drinkersMultivariable Cox modelModerate alcohol drinkersNorth American cohortCause-specific mortalityGrams/dayBaseline alcohol useSelf-reported alcohol useHigher alcohol useART initiationHCV statusCohort studyHazard ratioAdult PWHAlcohol drinkersAlcohol use dataCox modelPWHAmerican cohortMortalityRacial, Ethnic, and Rural Disparities in U.S. Veteran COVID-19 Vaccine Rates
Bernstein E, DeRycke E, Han L, Farmer M, Bastian L, Bean-Mayberry B, Bade B, Brandt C, Crothers K, Skanderson M, Ruser C, Spelman J, Bazan I, Justice A, Rentsch C, Akgün K. Racial, Ethnic, and Rural Disparities in U.S. Veteran COVID-19 Vaccine Rates. AJPM Focus 2023, 2: 100094. PMID: 37362395, PMCID: PMC10038675, DOI: 10.1016/j.focus.2023.100094.Peer-Reviewed Original ResearchRace/ethnicity groupsFirst vaccinationFirst COVID-19 vaccinationVeterans AffairsWhite veteransCharlson Comorbidity IndexRetrospective cohort studyPrimary care visitsEthnicity groupsCOVID-19 vaccinationLarge healthcare systemEquitable vaccine distributionAsian Americans/Pacific IslandersRace/ethnicityUnvaccinated patientsComorbidity indexInfluenza vaccinationSelf-reported categoriesBlack groupCare visitsCohort studyHazard ratioPrimary outcomeWhite patientsBlack patients
2022
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
MacKenna B, Kennedy NA, Mehrkar A, Rowan A, Galloway J, Matthewman J, Mansfield KE, Bechman K, Yates M, Brown J, Schultze A, Norton S, Walker AJ, Morton CE, Harrison D, Bhaskaran K, Rentsch CT, Williamson E, Croker R, Bacon S, Hickman G, Ward T, Davy S, Green A, Fisher L, Hulme W, Bates C, Curtis HJ, Tazare J, Eggo RM, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson LA, Mathur R, Wong AYS, Forbes H, Parry J, Hester F, Harper S, Douglas IJ, Smeeth L, Lees CW, Evans SJW, Goldacre B, Smith CH, Langan SM. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. The Lancet Rheumatology 2022, 4: e490-e506. PMID: 35698725, PMCID: PMC9179144, DOI: 10.1016/s2665-9913(22)00098-4.Peer-Reviewed Original ResearchImmune-mediated inflammatory diseasesCOVID-19-related deathsSevere COVID-19 outcomesImmune-modifying therapiesCritical care admissionInflammatory diseasesCOVID-19 outcomesImmune-modifying drugsHospital admissionGeneral populationCare admissionHazard ratioStandard systemic therapyStandard systemic treatmentSevere COVID-19Primary care recordsPrimary care dataNon-white ethnic groupsCohort studySystemic therapySystemic treatmentCox regressionPrescription dataCare recordsWhite ethnic groupAssociations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study
Trickey A, Zhang L, Gill MJ, Bonnet F, Burkholder G, Castagna A, Cavassini M, Cichon P, Crane H, Domingo P, Grabar S, Guest J, Obel N, Psichogiou M, Rava M, Reiss P, Rentsch CT, Riera M, Schuettfort G, Silverberg MJ, Smith C, Stecher M, Sterling TR, Ingle SM, Sabin CA, Sterne JAC. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. The Lancet HIV 2022, 9: e404-e413. PMID: 35659335, PMCID: PMC9647005, DOI: 10.1016/s2352-3018(22)00046-7.Peer-Reviewed Original ResearchConceptsIntegrase strand inhibitorsCause mortalityCohort studyThird drugAntiretroviral drugsMortality rateAntiretroviral Therapy Cohort CollaborationFirst-line ART regimensUK Collaborative HIV CohortART-naive peopleCollaborative HIV CohortAntiretroviral therapy regimensUK Medical Research CouncilMedical Research CouncilCohort CollaborationEfavirenz regimensVirological benefitVirological failureVirological suppressionART regimensHIV cohortHazard ratioRoutine careTherapy regimensUS National InstitutesAssociation between oral anticoagulants and COVID-19 related outcomes: a population-based cohort study
Wong AY, Tomlinson L, Brown JP, Elson W, Walker AJ, Schultze A, Morton CE, Evans D, Inglesby P, MacKenna B, Bhaskaran K, Rentsch CT, Powell E, Williamson E, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Cockburn J, McDonald HI, Mathur R, Wing K, Forbes H, Eggo RM, Evans SJ, Smeeth L, Goldacre B, Douglas IJ, . Association between oral anticoagulants and COVID-19 related outcomes: a population-based cohort study. British Journal Of General Practice 2022, 72: bjgp.2021.0689. PMID: 35440465, PMCID: PMC9037187, DOI: 10.3399/bjgp.2021.0689.Peer-Reviewed Original ResearchConceptsCOVID-19 outcomesPopulation-based cohort studySevere COVID-19 outcomesSARS-CoV-2Oral anticoagulantsLower riskVASc scoreCohort studyHazard ratioAtrial fibrillationCOVID-19 related outcomesCOVID-19-related deathsPrescribed oral anticoagulantsPrimary care dataBaseline stroke riskOAC useCurrent useStroke riskHospital admissionThrombotic eventsCox regressionOAC usersReduced infection riskGeneral practiceDeath records
2021
Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study
Wong A, Tomlinson L, Brown J, Elson W, Walker A, Schultze A, Morton C, Evans D, Inglesby P, MacKenna B, Bhaskaran K, Rentsch C, Powell E, Williamson E, Croker R, Bacon S, Hulme W, Bates C, Curtis H, Mehrkar A, Cockburn J, McDonald H, Mathur R, Wing K, Forbes H, Eggo R, Evans S, Smeeth L, Goldacre B, Douglas I. Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study. Journal Of Hematology & Oncology 2021, 14: 172. PMID: 34666811, PMCID: PMC8525065, DOI: 10.1186/s13045-021-01185-0.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsPopulation-based cohort studyCOVID-19-related outcomesSevere COVID-19Oral anticoagulantsCohort studyHazard ratioLower riskNegative control outcome analysisSevere COVID-19 diseaseNon-valvular atrial fibrillationPrimary care dataCOVID-19 outcomesCOVID-19COVID-19 diseaseNegative control outcomesDOAC usersOpenSAFELY platformWarfarin usersHospital admissionAtrial fibrillationClinical evidenceCox regressionResultsA totalOutcome analysisProtease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal Of Hepatology 2021, 75: 1312-1322. PMID: 34333102, PMCID: PMC8604762, DOI: 10.1016/j.jhep.2021.07.021.Peer-Reviewed Original ResearchConceptsSevere hepatic dysfunctionBaseline FIB-4Acute liver injuryHepatic dysfunctionInhibitor-based treatmentHepatic decompensationFIB-4Liver injuryHigh riskDAA therapyHazard ratioAdvanced liver fibrosis/cirrhosisRisk of ALIProtease inhibitor-based regimensProtease inhibitor-based treatmentLiver fibrosis/cirrhosisInhibitor-based regimensHepatitis C infectionSevere liver dysfunctionFibrosis/cirrhosisInhibitor-based therapyAminotransferase elevationChronic HCVALT elevationC infectionRisks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform
Williamson EJ, McDonald HI, Bhaskaran K, Walker AJ, Bacon S, Davy S, Schultze A, Tomlinson L, Bates C, Ramsay M, Curtis HJ, Forbes H, Wing K, Minassian C, Tazare J, Morton CE, Nightingale E, Mehrkar A, Evans D, Inglesby P, MacKenna B, Cockburn J, Rentsch CT, Mathur R, Wong AYS, Eggo RM, Hulme W, Croker R, Parry J, Hester F, Harper S, Douglas IJ, Evans SJW, Smeeth L, Goldacre B, Kuper H. Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform. The BMJ 2021, 374: n1592. PMID: 34261639, PMCID: PMC8278652, DOI: 10.1136/bmj.n1592.Peer-Reviewed Original ResearchConceptsCovid-19 related hospital admissionRelated hospital admissionsNon-COVID deathsHospital admissionOpenSAFELY platformDown syndromeCohort studyHazard ratioCerebral palsyDisability registersGeneral practiceCOVID-19COVID-19 hospital admissionsMain exposure groupsCOVID-19 vaccinationHospital admission dataPatient-level dataLow event ratesNon-COVID causesCOVID-19 testingTargeted preventive measuresWave 2Wave 1Electronic health recordsProfound learning disabilitiesAssociation between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England
Forbes H, Morton CE, Bacon S, McDonald HI, Minassian C, Brown JP, Rentsch CT, Mathur R, Schultze A, DeVito NJ, MacKenna B, Hulme WJ, Croker R, Walker AJ, Williamson EJ, Bates C, Mehrkar A, Curtis HJ, Evans D, Wing K, Inglesby P, Drysdale H, Wong AYS, Cockburn J, McManus R, Parry J, Hester F, Harper S, Douglas IJ, Smeeth L, Evans SJW, Bhaskaran K, Eggo RM, Goldacre B, Tomlinson LA. Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England. The BMJ 2021, 372: n628. PMID: 33737413, PMCID: PMC7970340, DOI: 10.1136/bmj.n628.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionIntensive care admissionHospital admissionCare admissionCohort studyCOVID-19Covid-19 related hospital admissionSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Wave 2Primary care dataRelated hospital admissionsSyndrome coronavirus 2Adults 65 yearsCohort of adultsCOVID-19 outcomesCoronavirus disease 2019COVID-19 mortalityRisk of infectionWave 1UK pandemicHazard ratioIntensive careAbsolute riskStatin exposure and risk of cancer in people with and without HIV infection.
Bedimo RJ, Park LS, Shebl FM, Sigel K, Rentsch CT, Crothers K, Rodriguez-Barradas MC, Goetz MB, Butt AA, Brown ST, Gibert C, Justice AC, Tate JP. Statin exposure and risk of cancer in people with and without HIV infection. AIDS 2021, 35: 325-334. PMID: 33181533, PMCID: PMC7775280, DOI: 10.1097/qad.0000000000002748.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyStatin useStatin exposureHazard ratioCancer riskLower riskPropensity score-matched cohortCox regression hazard ratiosAging Cohort StudyAnti-inflammatory effectsRegression hazard ratiosNon-Hodgkin lymphomaConfidence intervalsCancer registry linkagePropensity score-matched sampleRisk of cancerDeath overallUninfected patientsCohort studyIncident cancerRegistry linkageHIV infectionHIV statusStatin initiatorsUninfected persons
2020
HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform
Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, Eggo RM, Morton CE, Bacon SCJ, Inglesby P, Douglas IJ, Walker AJ, McDonald HI, Cockburn J, Williamson EJ, Evans D, Forbes HJ, Curtis HJ, Hulme WJ, Parry J, Hester F, Harper S, Evans SJW, Smeeth L, Goldacre B. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. The Lancet HIV 2020, 8: e24-e32. PMID: 33316211, PMCID: PMC7773630, DOI: 10.1016/s2352-3018(20)30305-2.Peer-Reviewed Original ResearchConceptsCOVID-19 deathsNational death registrationsPrimary care dataHazard ratioHIV infectionOpenSAFELY platformBlack ethnicityHealth Research Oxford Biomedical Research CentreElectronic primary care dataPopulation-based cohort analysisDeath registrationUK primary care dataCare dataLarge-scale population-based studyRetrospective cohort studyPrimary care recordsUK Medical Research CouncilPopulation-based studyRisk of deathHealth Data Research UKNon-black individualsNational InstituteCOVID-19 mortalityMedical Research CouncilBiomedical Research CentreRisk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform
Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, Rentsch CT, Williamson E, Drysdale H, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson L, Mathur R, Wing K, Wong AYS, Forbes H, Parry J, Hester F, Harper S, Evans SJW, Quint J, Smeeth L, Douglas IJ, Goldacre B, Collaborative O. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. The Lancet Respiratory Medicine 2020, 8: 1106-1120. PMID: 32979987, PMCID: PMC7515601, DOI: 10.1016/s2213-2600(20)30415-x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, InhalationAdolescentAdrenal Cortex HormonesAdultAgedAged, 80 and overAsthmaBetacoronavirusCohort StudiesCoronavirus InfectionsCOVID-19Electronic Health RecordsEnglandFemaleHumansMaleMiddle AgedMuscarinic AntagonistsPandemicsPneumonia, ViralProportional Hazards ModelsPulmonary Disease, Chronic ObstructiveRegression AnalysisSARS-CoV-2Young AdultConceptsChronic obstructive pulmonary diseaseCOVID-19-related deathsIndex dateObstructive pulmonary diseaseElectronic health recordsOpenSAFELY platformRespiratory medicationsCOPD cohortHazard ratioPulmonary diseaseAsthma cohortPrimary care electronic health recordsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2High-dose ICSHigh-dose ICSsRegular ICS useΒ-agonistsObservational cohort studyUK Medical Research CouncilRisk of deathCox regression modelAcute respiratory diseaseSyndrome coronavirus 2
2016
Baseline, Time-Updated, and Cumulative HIV Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality
Salinas JL, Rentsch C, Marconi VC, Tate J, Budoff M, Butt AA, Freiberg MS, Gibert CL, Goetz MB, Leaf D, Rodriguez-Barradas MC, Justice AC, Rimland D. Baseline, Time-Updated, and Cumulative HIV Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality. Clinical Infectious Diseases 2016, 63: 1423-1430. PMID: 27539575, PMCID: PMC5106607, DOI: 10.1093/cid/ciw564.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionIncident acute myocardial infarctionVeterans Aging Cohort StudyCombination antiretroviral therapyCardiovascular risk factorsHIV-1 RNAVACS IndexHazard ratioMyocardial infarctionRisk factorsMultivariable proportional hazards modelsVACS Index scoreLast clinic visitAging Cohort StudyHuman immunodeficiency virusProportional hazards modelCART initiationAntiretroviral therapyCause mortalityCD4 countClinic visitsCohort studyOrgan injuryPrimary outcomeImmunodeficiency virus